The Expanding Reach of the European Patent Office. Good for Health?
The European Patent Office (EPO) is tasked with the examination of patent applications and the granting of patents when these applications meet the patentability...
Time for new pharmaceutical-innovation models
The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year,...
Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....
Socially Responsible Licensing of Medical Technologies
GENEVA, SWITZERLAND: On 31 October, the World Trade Organization (WTO), the World Health Organization (WHO) and the World Intellectual Property Organization (WIPO) held their...
Uganda tells ARIPO: No more patents for pharmaceuticals
Uganda has notified the African Regional Intellectual Property Organisation (ARIPO) that pharmaceutical inventions are not eligible for patentability in the country, Managing IP reported.
With...
Corbyn’s Compulsory Licenses. Will they work?
On 24 September, Jeremy Corbyn, leader of the UK Labour party, announced a series of measures to bring medicines pricing in check and to...
Dutch Minister of Health writes open letter to pharma, threatens to name and shame
"Dear Pharma," writes the Dutch Minister of Health, Bruno Bruins in an open letter in the daily newspaper the Volkskrant, "Last week two messages jumped...
Cystic Fibrosis Buyers Club Shows the UK Government The Way
The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...
EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
Drug Price Transparency Calls Move from South Africa to World Health Assembly
by Katrina Perehudoff and Jennifer Sellin
Over 30 states and 40 business and civil society groups debated strategies for affordable and sustainable medicines prices at...